Durability of protection after single immunisation with genetically attenuated Plasmodium falciparum ∆mei2 (GA2) sporozoites – a follow-up, controlled human malaria rechallenge study

2024-513516-99-00 Phase I and Phase II (Integrated) - Other Ended

Start 28 Oct 2024 · End 17 Sep 2025 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ended
Participants planned 14
Countries 1
Sites 1

Falciparum malaria

Key facts

Sponsor
Leids Universitair Medisch Centrum (LUMC)
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Parasitic Diseases [C03]
Trial duration
28 Oct 2024 → 17 Sep 2025
Decision date (initial)
2024-10-07
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-513516-99-00
ClinicalTrials.gov
NCT06293339

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Falciparum malaria

VersionLevelCodeTermSystem organ class
23.0 PT 10083597 Malaria immunisation 100000004865
21.1 LLT 10016171 Falciparum malaria 10021881

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Leids Universitair Medisch Centrum (LUMC)

Sponsor organisation
Leids Universitair Medisch Centrum (LUMC)
Address
Albinusdreef 2
City
Leiden
Postcode
2333 ZA
Country
Netherlands

Scientific contact point

Organisation
Leids Universitair Medisch Centrum (LUMC)
Contact name
Meta Roestenberg

Public contact point

Organisation
Leids Universitair Medisch Centrum (LUMC)
Contact name
Meta Roestenberg

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 14 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Leids Universitair Medisch Centrum (LUMC)
Infectious Diseases (LU-CID), Albinusdreef 2, 2333 ZA, Leiden

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-10-28 2025-09-17 2025-01-08 2025-03-04

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-24 Netherlands Acceptable
2024-10-07
2024-10-07